There have been no prior investigations of the cost-effectiveness of transfusion strategies for trauma resuscitation. The Pragmatic, Randomized, Optimal Platelet and Plasma Ratios (PROPPR) study was a Phase III multisite, randomized trial in 680 subjects comparing the efficacy of 1:1:1 transfusion ratios of plasma and platelets to red blood cells with the 1:1:2 ratio. We hypothesized that 1:1:1 transfusion results in an acceptable incremental cost‐effectiveness ratio when estimated using patientsʼ age‐specific life expectancy and cost of care during the 30‐day PROPPR trial period.
STUDY DESIGN AND METHODS
International Classification of Diseases, Ninth Revision codes were prospectively collected, and subjects were matched 1:2 to subjects in the Healthcare Utilization Program State Inpatient Data to estimate cost weights. We used a decision tree analysis, combined with standard costs and estimated years of expected survival to determine the cost-effectiveness of the two treatments.
The 1:1:1 group had higher overall costs for the blood products but were more likely to achieve hemostasis and decreased hemorrhagic death by 24 hours (p = 0.006). For every 100 patients treated in the 1:1:1 group, eight more achieved hemostasis than in the 1:1:2 group. At 30 days, the total hospital cost per 100 patients was $5.6 million in the 1:1:1 group compared with $5.0 million in the 1:1:2 group. For each 100 patients, the 1:1:1 group had 218.5 more years of life expectancy. This was at a cost of $2994 per year gained.
The 1:1:1 transfusion ratio in severely injured hemorrhaging trauma patients is a very cost‐effective strategy for increasing hemostasis and decreasing trauma deaths.
#hemorrhage #HypovolemicShock #military #civilian #trauma #patients #combat #victims #prehospital #blood #IVfluid #IVwarmer #bloodwarmer #redcell #plasma #fluidresuscitation #resuscitation #severelyinjured #patients #bleeding #platelet #PROPPR